Post by Kanishk Kumar

Biologics CDMO Market 2034: Capacity Expansion and Outsourcing Surge Drive a $62 Billion Industry The biologics contract development and manufacturing organization (CDMO) market is experiencing remarkable growth as the biologics pipeline expands, outsourcing penetration rises, and substantial capacity investments reshape the global manufacturing landscape. Valued at approximately USD 23.00 billion in 2025, the #BiologicsCDMOMarket is projected to grow at a CAGR of 11.7% through 2034, reaching approximately USD 62.00 billion, according to DelveInsight. Key Developments in #BiologicsManufacturing 📰:- 🏭 In April 2025, Samsung Biologics began operations at its fifth plant within Bio Campus II in Songdo, Incheon, raising total capacity to 784,000 liters, with a sixth plant under review that would expand capacity to 964,000 liters—reinforcing its position as a global manufacturing leader. 🤝 In April 2025, Regeneron and FUJIFILM Biotechnologies signed a supply agreement valued at USD 3.0 billion for the manufacture of commercial biologics at Holly Springs, North Carolina. Leading #BiologicsCDMOCompanies include Lonza , Samsung Biologics, WuXi Biologics, Catalent, Thermo Fisher Scientific, FUJIFILM Biotechnologies , Boehringer Ingelheim(BioXcellence), AGC Biologics, Rentschler Biopharma, Syngene International Limited, and others. Explore DelveInsight's comprehensive report on the Biologics CDMO Market @https://lnkd.in/gTzSck9k #BiologicsCDMO #CDMO #BiologicsManufacturing #ContractManufacturing #Biopharma #mAbs #ADCs #CellAndGeneTherapy #DelveInsight #MarketResearch #PharmaOutsourcing #Biotech #ManufacturingCapacity #Lonza #SamsungBiologics #WuXiBiologics #Catalent #ThermoFisher #FUJIFILM #BoehringerIngelheim #Biomanufacturing #DrugDevelopment #PharmaSupplyChain #Oncology #Biosimilars #Biologics #PharmaIndustry #GlobalManufacturing #HealthcareInnovation